1. Events
  2. Live, Online

PBSS – INQOVI by Astex – Otsuka for the treatment of myelodysplastic syndromes (MDS)

Live, Online

Decitabine is a hypomethylating agent (HMA) and was approved by FDA for treatment of intermediate/high-risk MDS for IV infusion in 2006. Oral administration of decitabine, or other HMAs as single agent, has proven challenging as high first-pass due to metabolic degradation by cytidine deaminase (CDA) results in low bioavailability. Cedazuridine, a synthetic analog of tetradrouridine,..